Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Molecular Targets for Squamous NSCLC: Rounding Out Our ASCO 2012 Lung Cancer Highlights Presentations
Dr West
Author
Howard (Jack) West, MD

The last topic covered by Dr. Neal was on exciting work on molecular targets for squamous NSCLC. Long the poor stepchild to adenocarcinoma and other non-squamous subtypes, where new targets have been identified and several exciting targets tested and some now available, squamous NSCLC has largely been defined over the past few years by all of the things not appropriate for it: Avastin (bevacizumab) due to excessive bleeding risk, Alimta (pemetrexed) due to lack of activity, molecular testing for an EGFR mutation or ALK rearrangement due to a low probability of a positive result. But new work from a couple of different groups, as summarized by Dr. Neal, suggests that there are indeed potentially treatable molecular targets in squamous NSCLC, and this could lead to many new trials and therapeutic options for this subset of patients in the coming years.

Here are the video and audio versions of the podcast, along with the transcript and figures for this short program.

Dr. Neal ASCO 2012 LC Highlights Molec Targets Squamous NSCLC Audio Transcript

Dr. Neal ASCO 2012 LC Highlights 2012 Molec Targets Squamous NSCLC Transcript

Dr. Neal ASCO 2012 LC Highlights Molec Targets Squamous NSCLC Figs

We'll end with the question and answer session from that live program, coming up soon.

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Recent Comments

JOIN THE CONVERSATION
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on